Streetbeat News

Regulatory

WISH

ContextLogic Inc. has announced a plan to refocus its operations to support ongoing business prioritization efforts, better align resources, and improve operational efficiencies, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2023 | 3:00 pm

DBVT

DBV Technologies has received FDA support for its COMFORT Toddlers and COMFORT Children supplemental safety studies for peanut allergies. The studies will enroll children aged 1-7 years and aim to support the efficacy results from the EPITOPE and VITESSE Phase 3 pivotal studies. The company reported Q2 sales of $2.28 million, up from $1.53 million a year ago, and an EPS loss of $(0.26), down from $(0.35) a year ago. DBVT shares are up 8.11% at $1.60 during the premarket session.

Portfolio Pulse from Vandana Singh

August 01, 2023 | 2:59 pm

WISH

Trading of ContextLogic shares has been halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2023 | 2:54 pm

BTCUSD

Robert F. Kennedy Jr., a pro-Bitcoin presidential hopeful for the 2024 election, is gaining support among Republican voters, according to a poll from Morning Consult. However, his favorability among Democratic voters has declined. Kennedy Jr. ranks second behind President Joe Biden in the hypothetical vote. His stance on Bitcoin could be winning over voters who see crypto regulations as an important issue.

Portfolio Pulse from Chris Katje

August 01, 2023 | 2:40 pm

AMZN

Amazon has announced the nationwide expansion of its virtual health clinic service, Amazon Clinic. The platform connects users with healthcare providers for common conditions. The service is available in all 50 states and Washington, D.C., for video visits, while message-based chat is available in 32 states due to regulatory issues. Amazon Clinic does not accept insurance, but insurance can be used for medications prescribed through the service. The company has partnered with Curai Health, Hello Alpha, SteadyMD, and Wheel for the provision of telemedicine services.

Portfolio Pulse from Happy Mohamed

August 01, 2023 | 2:08 pm

DH

Definitive Healthcare has reported preliminary financial results for Q2 FY23, with expected revenue of $61.0 million and an adjusted net income of $12.3 million to $12.4 million. The company reaffirms its full year 2023 revenue and Adjusted EBITDA guidance. However, the company's previously issued financial statements should no longer be relied upon due to a restatement of historical financial results. This is due to a review of its sales tax positions, which revealed that sales in certain states were subject to sales tax that the company had not assessed. The company expects to record an aggregate increase to previously reported general and administrative expense of between $6.8 million to $10.2 million over the periods impacted.

Portfolio Pulse from Happy Mohamed

August 01, 2023 | 1:55 pm

CVII

Trading of Churchill Capital Corp shares has been halted due to pending news. The nature of the news is not yet disclosed.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2023 | 1:53 pm

JAGX

Jaguar Health (NASDAQ:JAGX) announced the activation of a physician-requested Investigational New Drug (IND) application by the FDA to evaluate crofelemer for treatment of uncontrolled diarrhea in a patient with short bowel syndrome (SBS). The trial is supported by Napo Pharmaceuticals, a Jaguar company. Crofelemer has been granted Orphan Drug Designation (ODD) by the FDA and the European Medicines Agency (EMA) for SBS and microvillus inclusion disease (MVID).

Portfolio Pulse from Happy Mohamed

August 01, 2023 | 1:51 pm

BLK

FXI

MSCI

SPY

The U.S. House of Representatives Select Committee on Chinese Communist Party has sent letters to Blackrock and MSCI. Blackrock has responded by stating that it complies with all applicable U.S. government laws and will continue to engage with the Select Committee directly on the issues raised.

Portfolio Pulse from Happy Mohamed

August 01, 2023 | 1:49 pm

ATXI

Avenue Therapeutics, Inc. (NASDAQ:ATXI) announced that its drug BAER-101 significantly suppressed seizures in a preclinical animal model of absence epilepsy. The drug demonstrated full suppression of seizure activity with a minimal effective dose. BAER-101 has previously been shown to be safe with minimal side effects in clinical studies by AstraZeneca. The company plans to initiate a Phase 2a study in 2024.

Portfolio Pulse from Happy Mohamed

August 01, 2023 | 1:48 pm